ArticleChembiochem : a European journal of chemical biology2026
Multienzyme Platform for the Synthesis of UDP Sugars and Human Milk Oligosaccharides.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Naturally occurring in breast milk, human milk oligosaccharides (HMOs) are of great interest as an ingredient for infant nutrition due to numerous associated health benefits. Current commercial production relies mainly on microbial fermentation, while enzymatic synthesis is used to produce milligram scales for scientific studies. Enzymatic synthesis using glycosyltransferases and nucleotide sugars is especially promising due to high reaction yields, but is limited by low activity of glycosyltransferases and the high cost of nucleotide sugars. This study presents a novel approach that uses a single engineered E. coli BL21(DE3) strain to simultaneously express six recombinant enzymes (UMPK, PPK3, GALK, NAHK, GALU, and PPA). This enables dual-nucleotide sugar synthesis through two integrated multienzyme cascades. The system uses cost-effective substrates, including uridine 5'-monophosphate (UMP), N-acetylglucosamine (GlcNAc), galactose (Gal), and ATP. In situ ATP regeneration is achieved through polyphosphate (PolyP
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.